March 27 (Reuters) - BridgeBio Pharma Inc BBIO.O:
BEYONTTRA™ (ACORAMIDIS), THE FIRST NEAR-COMPLETE TTR STABILIZER (≥90%), APPROVED IN JAPAN TO TREAT ATTR-CM
BRIDGEBIO PHARMA- WILL RECEIVE A $30 MILLION MILESTONE PAYMENT UPON APPROVAL IN JAPAN
BRIDGEBIO PHARMA INC - WILL GET ROYALTIES IN LOW DOUBLE DIGITS ON SALES OF ACORAMIDIS IN JAPAN
Source text: ID:nGNE6VhzHP
Further company coverage: BBIO.O
((Reuters.Briefs@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.